Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ EXOSC10 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5100508
Description
Antibody detects endogenous levels of total EXOSC10.
About 50% of patients with polymyositis/scleroderma (PM-Scl) overlap syndrome are reported to have autoantibodies to a nuclear/nucleolar particle termed PM-Scl. Exosome component 10 (EXOSC10), also named autoantigen PM/Scl-2, is the 100 kDa antigen component of PM-Scl and is recognized by most sera of PM-Scl patients. EXOSC10 is strongly enriched in the nucleolus and a small amount has been found in cytoplasm supporting the existence of a nucleolar RNA exosome complex form. As a putative catalytic component ofthe RNA exosome complex which has 3'->5' exoribonuclease activity, EXOSC10 participates in a multitude of cellular RNA processing and degradation events.
Specifications
EXOSC10 | |
Polyclonal | |
Unconjugated | |
EXOSC10 | |
Autoantigen PM/Scl 2; Autoantigen PM/Scl 2 homolog; autoantigen PM-SCL; Exosc10; Exosome component 10; P100 polymyositis-scleroderma overlap syndrome-associated autoantigen; p2; p3; p4; PM/Scl-100; PMSCL; PM-Scl; PMSCL2; Polymyositis/scleroderma autoantigen 100 kDa; polymyositis/scleroderma autoantigen 2; Polymyositis/scleroderma autoantigen 2 homolog; RRP6; Rrp6p | |
Rabbit | |
Affinity chromatography | |
RUO | |
313707, 50912, 5394 | |
-20°C | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
P56960, Q01780 | |
EXOSC10 | |
A synthesized peptide derived from human EXOSC10(Accession Q01780), corresponding to amino acid residues T196-T246. | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction